Brief: Uniqure Announces Strategic Reorganization To Reduce Operating Expenses And Support Advancement Of Multiple Clinical-Stage Programs

uniQure

05/10/2023 12:21

Oct 5 (Reuters) - Uniqure NV  UQ1.F :
    * UNIQURE ANNOUNCES STRATEGIC REORGANIZATION TO REDUCE
OPERATING
EXPENSES AND SUPPORT ADVANCEMENT OF MULTIPLE CLINICAL-STAGE
PROGRAMS
    * UNIQURE NV - REDUCTION OF 28% OF WORKFORCE NOT RELATED TO
HEMGENIX(®) MANUFACTURING OBLIGATIONS
    * UNIQURE NV - TOTAL COST SAVINGS OF $180 MILLION TO EXTEND
CASH
RUNWAY INTO Q2 OF 2027
    * UNIQURE NV - TOTAL COST SAVINGS OF $180 MILLION TO EXTEND
CASH
RUNWAY INTO Q2 OF 2027
    * UNIQURE NV - TOTAL COST SAVINGS OF $180 MILLION TO EXTEND
CASH
RUNWAY INTO Q2 OF 2027
    * UNIQURE NV - DISCONTINUING INVESTMENTS IN MORE THAN HALF
OF
RESEARCH AND TECHNOLOGY PROJECTS, CENTRALIZING OPERATIONS, AND
STREAMLINING ORGANIZATION
    * UNIQURE NV - AS A RESULT OF REPRIORITIZATION, RICARDO
DOLMETSCH,
CHIEF SCIENTIFIC OFFICER TO DEPART COMPANY
    * UNIQURE NV - ONE-TIME RESTRUCTURING COSTS OF APPROXIMATELY
$2.3
MILLION, PRIMARILY INCURRED IN Q4 OF 2023
    * UNIQURE NV - WILL ALSO CONSOLIDATE ALL GMP MANUFACTURING
INTO
ITS LEXINGTON, MA MANUFACTURING FACILITY
    * UNIQURE NV - CONSOLIDATE PROCESS AND ANALYTICAL
DEVELOPMENT INTO
ITS AMSTERDAM, NETHERLANDS FACILITY

Source text for Eikon:  ID:nGNX1xLKlQ 
Further company coverage:  UQ1.F 

 ((Reuters.Briefs@thomsonreuters.com))